Search research articles
Contact Us
Filters
Showing results (81-90 of 464) with videos related to
Page
of 47
Sort By:
BMJ (Clinical Research Ed.)
|
November 30, 2002
Efficacy, safety, and cost of new anticancer drugs. Pessimistic conclusion was not justified
Hilary Calvert, Duncan I Jodrell, James Cassidy, et al.
Frontiers in Oncology
|
October 14, 2014
The notch ligand JAGGED1 as a target for anti-tumor therapy
Demin Li, Massimo Masiero, Alison H Banham, et al.
Advances in Experimental Medicine and Biology
|
June 22, 2016
Methods: Using Three-Dimensional Culture (Spheroids) as an In Vitro Model of Tumour Hypoxia
Russell Leek, David Robert Grimes, Adrian L Harris, et al.
Cell Cycle (Georgetown, Tex.)
|
November 6, 2009
Role of ATF4 in regulation of autophagy and resistance to drugs and hypoxia
Tomasz Rzymski, Manuela Milani, Dean C Singleton, et al.
NPJ Breast Cancer
|
March 17, 2023
Matters Arising: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer
Ahmed M Alaa, Adrian L Harris, Mihaela van der Schaar
Trends in Cancer
|
October 2, 2024
Accessing the vasculature in cancer: revising an old hallmark
Adrian L Harris, David J Kerr, Francesco Pezzella, et al.
Current Drug Targets
|
March 9, 2016
Antiangiogenic Resistance and Cancer Metabolism: Opportunities for Synthetic Lethality
Simon Lord, Juan M Funes, Adrian L Harris, et al.
Nature Communications
|
December 12, 2018
Pan-cancer characterisation of microRNA across cancer hallmarks reveals microRNA-mediated downregulation of tumour suppressors
Andrew Dhawan, Jacob G Scott, Adrian L Harris, et al.
Cancer Research
|
March 18, 2021
The Landscape of the Heritable Cancer Genome
Viola Fanfani, Luca Citi, Adrian L Harris, et al.
Seminars in Cancer Biology
|
June 23, 2020
Dissecting the heritable risk of breast cancer: From statistical methods to susceptibility genes
Viola Fanfani, Martina Zatopkova, Adrian L Harris, et al.
Page
of 47
Search research articles
Search
Showing results (81-90 of 464) with videos related to
Sort By:
Page
of 47
BMJ (Clinical Research Ed.)
|
November 30, 2002
Efficacy, safety, and cost of new anticancer drugs. Pessimistic conclusion was not justified
Hilary Calvert, Duncan I Jodrell, James Cassidy, et al.
Frontiers in Oncology
|
October 14, 2014
The notch ligand JAGGED1 as a target for anti-tumor therapy
Demin Li, Massimo Masiero, Alison H Banham, et al.
Advances in Experimental Medicine and Biology
|
June 22, 2016
Methods: Using Three-Dimensional Culture (Spheroids) as an In Vitro Model of Tumour Hypoxia
Russell Leek, David Robert Grimes, Adrian L Harris, et al.
Cell Cycle (Georgetown, Tex.)
|
November 6, 2009
Role of ATF4 in regulation of autophagy and resistance to drugs and hypoxia
Tomasz Rzymski, Manuela Milani, Dean C Singleton, et al.
NPJ Breast Cancer
|
March 17, 2023
Matters Arising: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer
Ahmed M Alaa, Adrian L Harris, Mihaela van der Schaar
Trends in Cancer
|
October 2, 2024
Accessing the vasculature in cancer: revising an old hallmark
Adrian L Harris, David J Kerr, Francesco Pezzella, et al.
Current Drug Targets
|
March 9, 2016
Antiangiogenic Resistance and Cancer Metabolism: Opportunities for Synthetic Lethality
Simon Lord, Juan M Funes, Adrian L Harris, et al.
Nature Communications
|
December 12, 2018
Pan-cancer characterisation of microRNA across cancer hallmarks reveals microRNA-mediated downregulation of tumour suppressors
Andrew Dhawan, Jacob G Scott, Adrian L Harris, et al.
Cancer Research
|
March 18, 2021
The Landscape of the Heritable Cancer Genome
Viola Fanfani, Luca Citi, Adrian L Harris, et al.
Seminars in Cancer Biology
|
June 23, 2020
Dissecting the heritable risk of breast cancer: From statistical methods to susceptibility genes
Viola Fanfani, Martina Zatopkova, Adrian L Harris, et al.
Page
of 47